Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study
Abstract
Introduction Tuberculosis is a major public health problem, and its treatment has become challenging due to the emergence of drug-resistant tuberculosis. Since 2022, the World Health Organization has called for the rollout of the 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for the treatment of drug-resistant tuberculosis, but its effectiveness and safety are yet to be known in Ethiopia. Objective The aim of this study was to investigate the time to culture conversion, treatment outcomes, and safety of patients enrolled on BPaLM regimen in selected public hospitals in Ethiopia from September 2023 to July 2025. Methods A facility-based, retrospective cohort study was conducted on patients with drug-resistant tuberculosis who were enrolled on BPaLM and three treatment initiating centers were chosen as the study area due to the high volume of patients. The selected centers were St. Peter Specialized Hospital, All-Africa Leprosy, Tuberculosis, and Rehabilitation Training Centre, Comprehensive Specialized Hospital, and Dilla University Referral Hospital. Records of the patients were reviewed from the beginning to the end of treatment. Information on socio-demographic and clinical characteristics was extracted from patients’ charts and registries from May 1st 2025 to July 30 2025. All 104 patients who received the BPaLM regimen in the selected treatment initiating centers were included in the study. Descriptive statistical methods were presented as…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.